Tucker Asset Management LLC Has $12.74 Million Position in Amneal Pharmaceuticals, Inc. $AMRX

Tucker Asset Management LLC trimmed its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 9.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,011,064 shares of the company’s stock after selling 100,000 shares during the period. Amneal Pharmaceuticals accounts for approximately 3.7% of Tucker Asset Management LLC’s portfolio, making the stock its 6th largest holding. Tucker Asset Management LLC owned 0.32% of Amneal Pharmaceuticals worth $12,739,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of AMRX. Comerica Bank boosted its holdings in shares of Amneal Pharmaceuticals by 186.7% in the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after acquiring an additional 1,957 shares during the period. Spire Wealth Management boosted its holdings in shares of Amneal Pharmaceuticals by 66.6% in the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after acquiring an additional 1,023 shares during the period. Focus Partners Wealth bought a new position in shares of Amneal Pharmaceuticals in the third quarter worth $42,000. Advisory Services Network LLC bought a new position in shares of Amneal Pharmaceuticals in the third quarter worth $50,000. Finally, Strs Ohio bought a new position in shares of Amneal Pharmaceuticals in the fourth quarter worth $52,000. 31.82% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Deborah M. Autor sold 34,819 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $12.94, for a total transaction of $450,557.86. Following the completion of the transaction, the director directly owned 93,660 shares in the company, valued at $1,211,960.40. The trade was a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 17.30% of the stock is currently owned by insiders.

Amneal Pharmaceuticals Price Performance

Amneal Pharmaceuticals stock opened at $11.93 on Monday. Amneal Pharmaceuticals, Inc. has a 52 week low of $7.02 and a 52 week high of $15.42. The business has a 50-day simple moving average of $12.65 and a 200 day simple moving average of $12.83. The stock has a market cap of $3.81 billion, a price-to-earnings ratio of 31.40 and a beta of 1.32.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its earnings results on Thursday, May 7th. The company reported $0.27 EPS for the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%.The business had revenue of $722.52 million during the quarter. On average, research analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on AMRX shares. Zacks Research lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. UBS Group started coverage on Amneal Pharmaceuticals in a report on Friday, April 17th. They issued a “buy” rating and a $19.00 price target for the company. Weiss Ratings raised Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, May 11th. Finally, Truist Financial raised their price target on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Seven research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.